$41.945
-0.155[-0.37%]
Last update: 2:58PM Get Real Time Here
Cerevel Therapeutics Hldg
(NASDAQ:CERE)Cerevel Therapeutics Hldg Stock (NASDAQ:CERE), Analyst Ratings, Price Targets, Predictions
Cerevel Therapeutics Holdings Inc has a consensus price target of $38.13, established from looking at the 46 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, JP Morgan, and Jefferies on February 16, 2024, December 28, 2023, and December 22, 2023. With an average price target of $45 between Mizuho, JP Morgan, and Jefferies, there's an implied 7.28% upside for Cerevel Therapeutics Holdings Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
JP Morgan
Jefferies
TD Cowen
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cerevel Therapeutics Hldg
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/16/2024 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 7.28% | Mizuho | Graig Suvannavejh | $25 → $45 | Maintains | Neutral | Get Alert |
| 12/28/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 7.28% | JP Morgan | Jessica Fye | $25 → $45 | Maintains | Neutral | Get Alert |
| 12/22/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 7.28% | Jefferies | Michael Yee | $40 → $45 | Downgrade | Buy → Hold | Get Alert |
| 12/08/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 7.28% | TD Cowen | Joseph Thome | → $45 | Downgrade | Outperform → Market Perform | Get Alert |
| 12/07/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 7.28% | HC Wainwright & Co. | Douglas Tsao | $41 → $45 | Downgrade | Buy → Neutral | Get Alert |
| 12/07/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 7.28% | Piper Sandler | David Amsellem | $33 → $45 | Downgrade | Overweight → Neutral | Get Alert |
| 12/07/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 7.28% | Cantor Fitzgerald | Charles Duncan | $38 → $45 | Downgrade | Overweight → Neutral | Get Alert |
| 11/20/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -40.4% | JP Morgan | Jessica Fye | → $25 | Reinstates | → Neutral | Get Alert |
| 11/02/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -9.41% | Morgan Stanley | Matthew Harrison | $42 → $38 | Maintains | Overweight | Get Alert |
| 09/28/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -21.33% | Piper Sandler | David Amsellem | → $33 | Initiates | → Overweight | Get Alert |
| 08/07/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -40.4% | Mizuho | Graig Suvannavejh | $29 → $25 | Maintains | Neutral | Get Alert |
| 08/03/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 0.13% | Morgan Stanley | Matthew Harrison | $46 → $42 | Maintains | Overweight | Get Alert |
| 08/03/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -26.09% | B of A Securities | Tazeen Ahmad | $36 → $31 | Downgrade | Buy → Neutral | Get Alert |
| 08/03/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -2.25% | HC Wainwright & Co. | Douglas Tsao | $45 → $41 | Maintains | Buy | Get Alert |
| 05/23/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -28.48% | Goldman Sachs | Madhu Kumar | $31 → $30 | Maintains | Neutral | Get Alert |
| 05/08/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -30.86% | Mizuho | Graig Suvannavejh | $26 → $29 | Maintains | Neutral | Get Alert |
| 05/04/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | -28.48% | Wells Fargo | Mohit Bansal | → $30 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/10/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | — | TD Cowen | Joseph Thome | — | Initiates | → Outperform | Get Alert |
| 04/03/2023 | CERE | Buy Now | Cerevel Therapeutics Hldg | $41.95 | 7.28% | HC Wainwright & Co. | Douglas Tsao | → $45 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Cerevel Therapeutics Hldg (CERE)?
The latest price target for Cerevel Therapeutics Hldg (NASDAQ: CERE) was reported by Mizuho on February 16, 2024. The analyst firm set a price target for $45.00 expecting CERE to rise to within 12 months (a possible 7.28% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cerevel Therapeutics Hldg (CERE)?
The latest analyst rating for Cerevel Therapeutics Hldg (NASDAQ: CERE) was provided by Mizuho, and Cerevel Therapeutics Hldg maintained their neutral rating.
When was the last upgrade for Cerevel Therapeutics Hldg (CERE)?
The last upgrade for Cerevel Therapeutics Holdings Inc happened on May 4, 2023 when Wells Fargo raised their price target to $30. Wells Fargo previously had an equal-weight for Cerevel Therapeutics Holdings Inc.
When was the last downgrade for Cerevel Therapeutics Hldg (CERE)?
The last downgrade for Cerevel Therapeutics Holdings Inc happened on December 22, 2023 when Jefferies changed their price target from $40 to $45 for Cerevel Therapeutics Holdings Inc.
When is the next analyst rating going to be posted or updated for Cerevel Therapeutics Hldg (CERE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cerevel Therapeutics Hldg, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cerevel Therapeutics Hldg was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.
Is the Analyst Rating Cerevel Therapeutics Hldg (CERE) correct?
While ratings are subjective and will change, the latest Cerevel Therapeutics Hldg (CERE) rating was a maintained with a price target of $25.00 to $45.00. The current price Cerevel Therapeutics Hldg (CERE) is trading at is $41.95, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.